A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2.
Catharine I PaulesJing WangKay M TomashekTyler BonnettKanal SinghMahomed-Yunus MoosaRichard T DaveyDavid Chien Boon LyeLori E DoddOtto O YangConstance A BensonGregory A DeyeSarah B DoernbergNoreen A HynesRobert GrossbergCameron R WolfeSeema U NayakWilliam R ShortJocelyn VoellGail E PotterRekha R RapakaPublished in: Annals of internal medicine (2024)
National Institute of Allergy and Infectious Diseases.